US pays $1B to nearly double supply of Merck's COVID-19 pill

The U.S. government has agreed to pay Merck & Co. about $1 billion for another 1.4 million treatment courses of its COVID-19 pill molnupiravir, nearly doubling its stockpile ahead of potential Food and Drug Administration authorization next month.